Article

Malignant phyllodes tumor of the prostate and seminal vesicle: an unusual presentation


 

A 58-year-old man was admitted to hospital with gross hematuria and a history of a prostate nodule that had been unchanged in size over a period of 3 years. A digital rectal examination revealed a nodule, confirmed by pelvic computed tomography and magnetic resonance imaging scans. Microscopic findings from a transrectal ultrasound-guided biopsy of the prostate revealed phyllodes tumor of the prostate and seminal vesicle, with well-differentiated fibrosarcoma and undifferentiated sarcoma. An initial prostate-specific antigen (PSA) value was 2 ng/mL (normal, less than 4 ng/dL). Over time, the mass grew in size and caused abdominal bloating, bladder outlet obstruction, and kidney failure. A radical prostatectomy was performed and the patient had an uneventful postoperative course. Thereafter, the patient received adjuvant radiation therapy. A few months after surgery, the symptoms worsened and imaging revealed a recurrence and metastasis to his lungs. The patient is currently receiving palliative chemotherapy.

*Click on the link to the left for a PDF of the full article.

Recommended Reading

Abdominal, thoracic CT scans reliably detect incidental low lumbar BMD
MDedge Hematology and Oncology
DNA changes predict prostate cancer death
MDedge Hematology and Oncology
Obesity linked to prostatic intraepithelial neoplasia
MDedge Hematology and Oncology
FDA advisory panel decides tivozanib falls short for advanced renal cell carcinoma
MDedge Hematology and Oncology
Forecast warns of urologist shortage
MDedge Hematology and Oncology
FDA approves radiotherapy for metastatic prostate cancer
MDedge Hematology and Oncology
Postop surveillance sufficient for stage I testicular cancer
MDedge Hematology and Oncology
Consequences of not screening for prostate cancer prove dire
MDedge Hematology and Oncology
New test beats PSA in predicting significant prostate Ca
MDedge Hematology and Oncology
Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index
MDedge Hematology and Oncology